Adult Glioblastoma
80
2
4
54
Key Insights
Highlights
Success Rate
73% trial completion
Published Results
39 trials with published results (49%)
Research Maturity
54 completed trials (68% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
25.0%
20 terminated out of 80 trials
73.0%
-13.5% vs benchmark
0%
0 trials in Phase 3/4
72%
39 of 54 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 54 completed trials
Clinical Trials (80)
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma
Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
Response Prediction for Anti-angiogenic Treatment in Recurrent Glioblastoma
Advanced MR Imaging as Predictor of Treatment Response in Newly Diagnosed Glioblastomas
Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma
Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma
Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma
Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme
Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma